Natus Medical Inc (NASDAQ:BABY) shares reached a new 52-week low during trading on Wednesday . The company traded as low as $28.15 and last traded at $28.15, with a volume of 711562 shares changing hands. The stock had previously closed at $28.80.

A number of research firms recently commented on BABY. Benchmark reaffirmed a “buy” rating and issued a $49.00 target price (down from $55.00) on shares of Natus Medical in a research report on Tuesday. Zacks Investment Research downgraded shares of Natus Medical from a “hold” rating to a “strong sell” rating in a research report on Thursday, January 11th. William Blair downgraded shares of Natus Medical from an “outperform” rating to a “market perform” rating in a research report on Monday, January 8th. Finally, BidaskClub downgraded shares of Natus Medical from a “sell” rating to a “strong sell” rating in a research report on Saturday, January 6th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $47.00.

The company has a debt-to-equity ratio of 0.36, a quick ratio of 3.36 and a current ratio of 4.21. The company has a market capitalization of $876.99, a PE ratio of -317.19 and a beta of 0.84.

Natus Medical (NASDAQ:BABY) last posted its earnings results on Wednesday, October 25th. The medical equipment provider reported $0.40 EPS for the quarter, beating the Zacks’ consensus estimate of $0.38 by $0.02. The firm had revenue of $122.60 million for the quarter, compared to the consensus estimate of $122.41 million. Natus Medical had a negative net margin of 0.62% and a positive return on equity of 12.06%. The company’s revenue was up 34.9% on a year-over-year basis. During the same period last year, the firm posted $0.39 EPS. sell-side analysts expect that Natus Medical Inc will post 1.64 EPS for the current fiscal year.

In related news, VP Dong Chune Christopher Chung sold 12,642 shares of the stock in a transaction on Monday, November 6th. The shares were sold at an average price of $42.91, for a total transaction of $542,468.22. Following the completion of the sale, the vice president now owns 141,414 shares in the company, valued at approximately $6,068,074.74. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director William M. Moore sold 5,000 shares of the stock in a transaction on Monday, November 13th. The stock was sold at an average price of $41.01, for a total transaction of $205,050.00. The disclosure for this sale can be found here. 5.50% of the stock is owned by corporate insiders.

A number of large investors have recently modified their holdings of the stock. Pinebridge Investments L.P. boosted its stake in Natus Medical by 1.7% during the 2nd quarter. Pinebridge Investments L.P. now owns 4,359 shares of the medical equipment provider’s stock worth $163,000 after purchasing an additional 71 shares during the period. Victory Capital Management Inc. boosted its stake in Natus Medical by 17.6% during the 2nd quarter. Victory Capital Management Inc. now owns 3,744 shares of the medical equipment provider’s stock worth $140,000 after purchasing an additional 560 shares during the period. Alliancebernstein L.P. boosted its stake in Natus Medical by 2.3% during the 2nd quarter. Alliancebernstein L.P. now owns 53,756 shares of the medical equipment provider’s stock worth $2,005,000 after purchasing an additional 1,190 shares during the period. Riverhead Capital Management LLC boosted its stake in Natus Medical by 90.9% during the 2nd quarter. Riverhead Capital Management LLC now owns 2,864 shares of the medical equipment provider’s stock worth $107,000 after purchasing an additional 1,364 shares during the period. Finally, American International Group Inc. boosted its stake in Natus Medical by 5.7% during the 3rd quarter. American International Group Inc. now owns 25,767 shares of the medical equipment provider’s stock worth $966,000 after purchasing an additional 1,398 shares during the period. Hedge funds and other institutional investors own 99.87% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Natus Medical (BABY) Hits New 12-Month Low at $28.15” was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at https://theolympiareport.com/2018/01/19/natus-medical-baby-hits-new-12-month-low-at-28-15.html.

About Natus Medical

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.